A Phase 2 interventional study of Clazakizumab and Placebo (Matching with Clazakizumab) in Rheumatoid Arthritis, sponsored by CSL Behring. Completed at 55 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-12.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 353rd largest by enrollment of the 771 interventional ones that give a count, is one of 53 that started in 2012, is one of 215 in phase 2, and was the 538th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 53 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 802 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to identify an appropriate dose of study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
Drug: Clazakizumab
Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
Drug: Clazakizumab
Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
Drug: Clazakizumab
Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
Drug: Placebo (Matching with Clazakizumab)
Also known as: BMS-945429
Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12
DAS28-CRP describes severity of rheumatoid arthritis. The components of the joint count assessment are shoulder, elbow, wrist, metacarpophalangeal joints 1 through 5, proximal interphalangeal joints 1 through 5, and the knee joints on the right and left sides, whereby the number of affected joints, tender and swollen, respectively, are counted. The formula used to calculate the score is: DAS28-CRP=0.56 \\times \\sqrt{TEN28} + 0.28 \\times \\sqrt{SW28} + 0.36 \\times \\ln(CRP+1) + 0.014 \\times SA+0.96 with: TEN28: number of joints with tenderness upon touching SW28: number of swollen joints CRP: C-reactive Protein SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale between 0 and 100 ("0":no activity, "100": highest activity possible). DAS-CRP score range is 0.49 to 9.07 A DAS-CRP value \>5.1 corresponds to a high disease activity A DAS-28 reduction by 0.6 represents a moderate improvement. A reduction \>1.2 represents a major improvement
Time frame: Baseline and Week 12
American College of Rheumatology (ACR) 20/50/70 Response Rates
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At week 12
Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
Time frame: Baseline and week 12
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
Time frame: Baseline and week 12
Boolean Remission at Week 12
Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)
Time frame: At week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12
Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.
Time frame: Baseline and Week 12
Percent of Participants With a DAS28-Erythrocyte Sedimentation Rate (ESR) <2.6
DAS28- ESR = Disease Activity Scores 28 based on erythrocyte sedimentation rate. A DAS28-ESR below 2.6 is interpreted as remission.
Time frame: At week 12
Percent of Participants With a DAS28-C Reactive Protein (CRP) <2.6
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
Time frame: At week 12
| Milestone | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Started | 40 | 21 | 42 | 40 |
| Completed | 35 | 17 | 35 | 36 |
| Not completed | 5 | 4 | 7 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Subject request to discontinue study treatment | 1 | 1 | 2 | 1 |
| Withdrew: Subject no longer meets study criteria | 0 | 1 | 0 | 0 |
DAS28-CRP describes severity of rheumatoid arthritis. The components of the joint count assessment are shoulder, elbow, wrist, metacarpophalangeal joints 1 through 5, proximal interphalangeal joints 1 through 5, and the knee joints on the right and left sides, whereby the number of affected joints, tender and swollen, respectively, are counted. The formula used to calculate the score is: DAS28-CRP=0.56 \\times \\sqrt{TEN28} + 0.28 \\times \\sqrt{SW28} + 0.36 \\times \\ln(CRP+1) + 0.014 \\times SA+0.96 with: TEN28: number of joints with tenderness upon touching SW28: number of swollen joints CRP: C-reactive Protein SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale between 0 and 100 ("0":no activity, "100": highest activity possible). DAS-CRP score range is 0.49 to 9.07 A DAS-CRP value \>5.1 corresponds to a high disease activity A DAS-28 reduction by 0.6 represents a moderate improvement. A reduction \>1.2 represents a major improvement
| score on a scale | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12 | -0.75 ± 0.22 | -1.10 ± 0.33 | -2.10 ± 0.22 | -2.43 ± 0.22 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of responders | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| ARC20 responders | 27.5 | 14.3 | 50.0 | 47.5 |
| ARC50 responders | 7.5 | 14.3 | 21.4 | 22.5 |
| ARC70 responders | 2.5 | 4.8 | 9.5 | 15.0 |
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
| score on a scale | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12 | -9.9 ± 2.656 | -12.8 ± 3.961 | -17.4 ± 2.545 | -21.6 ± 2.539 |
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
| score on a scale | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12 | -9.68 ± 2.6846 | -13.08 ± 4.0011 | -20.15 ± 2.5928 | -24.02 ± 2.5677 |
Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)
| percentage of participants | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Boolean Remission at Week 12 | 5.0 | 4.8 | 2.4 | 5.0 |
Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.
| score on a scale | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12 | -0.25 ± 0.0906 | -0.09 ± 0.1307 | -0.31 ± 0.0889 | -0.46 ± 0.0905 |
DAS28- ESR = Disease Activity Scores 28 based on erythrocyte sedimentation rate. A DAS28-ESR below 2.6 is interpreted as remission.
| percentage of participants | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Percent of Participants With a DAS28-Erythrocyte Sedimentation Rate (ESR) <2.6 | 2.5 | 4.8 | 7.1 | 15.0 |
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
| percentage of participants | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| Percent of Participants With a DAS28-C Reactive Protein (CRP) <2.6 | 5.0 | 9.5 | 14.3 | 15.0 |
Collected over Up to 12 weeks for each participant. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Methotrexate (MTX) | 1/40 (2.5%) | 1/40 (2.5%) | 14/40 (35%) |
| Clazakizumab (1 mg) + MTX | 0/21 (0%) | 0/21 (0%) | 5/21 (23.8%) |
| Clazakizumab (5 mg) + MTX | 0/42 (0%) | 0/42 (0%) | 24/42 (57.1%) |
| Clazakizumab (25 mg) + MTX | 0/40 (0%) | 1/40 (2.5%) | 28/40 (70%) |
| Event | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| SUDDEN DEATHGeneral disorders | 1/40 | 0/21 | 0/42 | 0/40 |
| VIRAL INFECTIONInfections and infestations | 0/40 | 0/21 | 0/42 | 1/40 |
| RENAL IMPAIRMENTRenal and urinary disorders | 1/40 | 0/21 | 0/42 | 0/40 |
| Event | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 3/40 | 0/21 | 1/42 | 1/40 |
| INJECTION SITE REACTIONGeneral disorders | 0/40 | 0/21 | 1/42 | 3/40 |
| LEUKOPENIABlood and lymphatic system disorders | 0/40 | 0/21 | 1/42 | 3/40 |
| NEUTROPENIABlood and lymphatic system disorders | 0/40 | 0/21 | 0/42 | 3/40 |
| SINUSITISInfections and infestations | 2/40 | 0/21 | 1/42 | 0/40 |
| CONTUSIONInjury, poisoning and procedural complications | 2/40 | 1/21 | 0/42 | 0/40 |
| DYSLIPIDAEMIAMetabolism and nutrition disorders | 0/40 | 0/21 | 1/42 | 2/40 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/40 | 0/21 | 1/42 | 2/40 |
| DIZZINESSNervous system disorders | 2/40 | 0/21 | 0/42 | 1/40 |
| ORAL HERPESInfections and infestations | 2/40 | 0/21 | 0/42 | 0/40 |
| Age, Categorical(Participants) | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 32 | 15 | 35 | 32 | 114 |
| >=65 years | 8 | 6 | 7 | 8 | 29 |
| Age, Continuous(years) | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX | Total |
|---|---|---|---|---|---|
| Mean | 54.4 ± 11.21 | 55.8 ± 11.20 | 53.4 ± 13.75 | 52.6 ± 13.21 | 53.8 ± 12.48 |
| Sex: Female, Male(Participants) | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX | Total |
|---|---|---|---|---|---|
| Female | 35 | 18 | 33 | 35 | 121 |
| Male | 5 | 3 | 9 | 5 | 22 |
| Region of Enrollment(participants) | Placebo + Methotrexate (MTX) | Clazakizumab (1 mg) + MTX | Clazakizumab (5 mg) + MTX | Clazakizumab (25 mg) + MTX | Total |
|---|---|---|---|---|---|
| Canada | 1 | 1 | 3 | 0 | 5 |
| Argentina | 4 | 4 | 4 | 6 | 18 |
| Hungary | 7 | 3 | 7 | 5 | 22 |
| United States | 11 | 7 | 11 | 9 | 38 |
| Japan | 4 | 3 | 5 | 4 | 16 |
| Italy | 1 | 0 | 0 | 0 | 1 |
| Mexico | 8 | 1 | 8 | 12 | 29 |
| South Africa | 4 | 2 | 2 | 4 | 12 |
| France | 0 | 0 | 2 | 0 | 2 |
Ran from Jun 2012 to primary completion in Jun 2013, 12 months.
Results were first posted in Apr 2021, 7 years 10 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab